Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 746486, 10 pages
http://dx.doi.org/10.1155/2013/746486
Review Article

Significance of Kampo, Traditional Japanese Medicine, in Supportive Care of Cancer Patients

1Department of General Medicine, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
2Department of Medical Oncology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
3Department of Anesthesiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
4Department of Obstetrics and Gynecology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
5Department of Pharmacology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan

Received 19 March 2013; Accepted 28 May 2013

Academic Editor: Sookyung Lee

Copyright © 2013 Jun-ichi Yamakawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Ferrara and C. A. Schiffer, “Acute myeloid leukaemia in adults,” The Lancet, vol. 381, pp. 484–495, 2013. View at Google Scholar
  2. A. Pennathur, M. K. Gibson, B. A. Jobe et al., “Oesophageal carcinoma,” The Lancet, vol. 381, pp. 400–412, 2013. View at Google Scholar
  3. T. Waddell and D. Cunningham, “Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours,” British Journal of Surgery, vol. 100, pp. 5–14, 2013. View at Google Scholar
  4. T. C. Chua and A. Saxena, “Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results,” Surgical Oncology, vol. 20, no. 4, pp. e161–e168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. L. T. MacEdo, J. Ribeiro, G. Curigliano et al., “Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma,” European Journal of Surgical Oncology, vol. 37, no. 7, pp. 558–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. J. Liu, J. Lu, and M. J. McKeage, “Membrane transporters as determinants of the pharmacology of platinum anticancer drugs,” Current Cancer Drug Targets, vol. 12, pp. 962–986, 2012. View at Google Scholar
  7. X. Song, S. R. Long, B. Barber et al., “Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer,” Current Clinical Pharmacology, vol. 7, no. 1, pp. 56–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Deenen, A. Cats, J. H. Beijnen, and J. H. M. Schellens, “Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism,” Oncologist, vol. 16, no. 6, pp. 820–834, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. E. S. Hsu, “A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics,” American Journal of Therapeutics, vol. 17, no. 5, pp. 476–486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Lee, M. Gianos, and W. B. Klaustermeyer, “Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents,” Annals of Allergy, Asthma and Immunology, vol. 102, no. 3, pp. 179–187, 2009. View at Google Scholar · View at Scopus
  11. J. Bardy, N. J. Slevin, K. L. Mais, and A. Molassiotis, “A systematic review of honey uses and its potential value within oncology care,” Journal of Clinical Nursing, vol. 17, no. 19, pp. 2604–2623, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Grande, M. J. Villanueva, G. Huidobro, and J. Casal, “Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment,” Clinical and Translational Oncology, vol. 9, no. 9, pp. 578–581, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. E. A. Rodriguez-Frias and W. M. Lee, “Cancer chemotherapy II: atypical hepatic injuries,” Clinics in Liver Disease, vol. 11, no. 3, pp. 663–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. A. Rodriguez-Frias and W. M. Lee, “Cancer chemotherapy I: hepatocellular injury,” Clinics in Liver Disease, vol. 11, no. 3, pp. 641–662, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T. M. Bosch, I. Meijerman, J. H. Beijnen, and J. H. M. Schellens, “Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer,” Clinical Pharmacokinetics, vol. 45, no. 3, pp. 253–285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Ando, Y. Hasegawa, and Y. Ando, “Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan,” Investigational New Drugs, vol. 23, no. 6, pp. 539–545, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Ando and Y. Hasegawa, “Clinical pharmacogenetics of irinotecan (CPT-11),” Drug Metabolism Reviews, vol. 37, no. 3, pp. 565–574, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. R.-J. Bensadoun, N. Magné, P.-Y. Marcy, and F. Demard, “Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment,” European Archives of Oto-Rhino-Laryngology, vol. 258, no. 9, pp. 481–487, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. R. L. Nahin, “Use of the best case series to evaluate complementary and alternative therapies for cancer: a systematic review,” Seminars in Oncology, vol. 29, no. 6, pp. 552–562, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. D. White, “Complementary and alternative medicine research: a National Cancer Institute perspective,” Seminars in Oncology, vol. 29, no. 6, pp. 546–551, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Richardson and S. E. Straus, “Complementary and alternative medicine: opportunities and challenges for cancer management and research,” Seminars in Oncology, vol. 29, no. 6, pp. 531–545, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. D. White, “The National Cancer Institute's perspective and agenda for promoting awareness and research on alternative therapies for cancer,” Journal of Alternative and Complementary Medicine, vol. 8, no. 5, pp. 545–550, 2002. View at Google Scholar · View at Scopus
  23. L. A. Walker and S. Budd, “UK: the current state of regulation of complementary and alternative medicine,” Complementary Therapies in Medicine, vol. 10, no. 1, pp. 8–13, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. J. D. White, “Cancer: current research in alternative therapies,” Primary Care, vol. 29, pp. 379–392, 2002. View at Google Scholar
  25. M. Markman, “Safety issues in using complementary and alternative medicine,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 39–41, 2002. View at Google Scholar · View at Scopus
  26. T. Tsutsui and N. Muramatsu, “Japan's universal long-term care system reform of 2005: containing costs and realizing a vision,” Journal of the American Geriatrics Society, vol. 55, no. 9, pp. 1458–1463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Ikegami, “The economics of health care in Japan,” Science, vol. 258, pp. 614–618, 1992. View at Google Scholar
  28. K. Terasawa, “Evidence-based reconstruction of Kampo medicine: part I-is Kampo CAM?” Evidence-Based Complementary and Alternative Medicine, vol. 1, pp. 11–16, 2004. View at Google Scholar
  29. K. Terasawa, “Evidence-based reconstruction of Kampo medicine: part II-the concept of Sho,” Evidence-Based Complementary and Alternative Medicine, vol. 1, pp. 119–123, 2004. View at Google Scholar
  30. K. Terasawa, “Evidence-based reconstruction of Kampo medicine: part-III-how should Kampo be evaluated?” Evidence-Based Complementary and Alternative Medicine, vol. 1, pp. 219–222, 2004. View at Google Scholar
  31. Y. Motoo, T. Seki, and K. Tsutani, “Traditional Japanese medicine, Kampo: its history and current status,” Chinese Journal of Integrative Medicine, vol. 17, no. 2, pp. 85–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Iwase, T. Yamaguchi, T. Miyaji et al., “The clinical use of Kampo medicines (traditional Japanese herbal treatments) for controlling cancer patients' symptoms in Japan: a national cross-sectional survey,” BMC Complementary and Alternative Medicine, vol. 20, article 222, 2012. View at Google Scholar
  33. K. Ogawa, T. Omatsu, C. Matsumoto et al., “Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect,” BMC Complementary and Alternative Medicine, vol. 9, article 118, 2012. View at Google Scholar
  34. J. J. Gao, P. P. Song, F. H. Qi et al., “Evidence-based research on traditional Japanese medicine, Kampo, in treatment of gastrointestinal cancer in Japan,” Drug Discoveries & Therapeutics, vol. 6, pp. 1–8, 2012. View at Google Scholar
  35. H. Yasunaga, H. Miyata, H. Horiguchi, K. Kuwabara, H. Hashimoto, and S. Matsuda, “Effect of the Japanese herbal kampo medicine Dai-kenchu-to on postoperative adhesive small bowel obstruction requiring long-tube decompression: a propensity score analysis,” Evidence-based Complementary and Alternative Medicine, vol. 2011, Article ID 264289, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Sharma, P. Tobin, and S. J. Clarke, “Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea,” The Lancet Oncology, vol. 6, no. 2, pp. 93–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Mori, T. Kondo, Y. Kamiyama, Y. Kano, and K. Tominaga, “Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 5, pp. 403–406, 2003. View at Google Scholar · View at Scopus
  38. W. T. Lim, E. H. Tan, C. K. Toh et al., “Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors,” Annals of Oncology, vol. 21, no. 2, Article ID mdp315, pp. 382–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. N. Fornier, “Epothilones in breast cancer: review of clinical experience,” Annals of Oncology, vol. 18, no. 5, pp. v16–v21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Hilpert, A. Stähle, O. Tomé et al., “Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group,” Supportive Care in Cancer, vol. 13, no. 10, pp. 797–805, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. J. Edelman, “Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials,” Clinical Lung Cancer, vol. 4, pp. 40–44, 2003. View at Google Scholar
  42. A. D. Seidman, J. O'Shaughnessy, and J.-L. Misset, “Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?” Oncologist, vol. 7, no. 6, pp. 20–28, 2002. View at Google Scholar · View at Scopus
  43. C. Nicolaides, M. A. Dimopoulos, E. Samantas et al., “Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group,” Annals of Oncology, vol. 11, no. 7, pp. 873–875, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Ami, K. Okamoto, and H. Oshima, “Analgesic effect of magnetic stimulation on paclitaxel-induced peripheral neuropathic pain in mice,” Brain Research, vol. 21, pp. 24–29, 2012. View at Google Scholar
  45. C. Tofthagen, J. Overcash, and K. Kip, “Falls in persons with chemotherapy-induced peripheral neuropathy,” Supportive Care in Cancer, vol. 20, no. 3, pp. 583–589, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. M. H. Cohen, P. Cortazar, R. Justice, and R. Pazdur, “Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC),” Oncologist, vol. 15, no. 12, pp. 1352–1358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Tofthagen, “Patient perceptions associated with chemotherapy-induced peripheral neuropathy,” Clinical Journal of Oncology Nursing, vol. 14, no. 3, pp. E22–E28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. E. K. Joseph and J. D. Levine, “Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat,” Journal of Pain, vol. 10, no. 5, pp. 534–541, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. S. R. McWhinney, R. M. Goldberg, and H. L. McLeod, “Platinum neurotoxicity pharmacogenetics,” Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 10–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. F. V. Piantedosi, F. Caputo, G. Mazzarella et al., “Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study,” Cancer Chemotherapy and Pharmacology, vol. 61, no. 5, pp. 803–807, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. Y.-M. Chen, R.-P. Perng, J.-F. Shih, C.-M. Tsai, and J. Whang-Peng, “Chemotherapy for non-small cell lung cancer in elderly patients,” Chest, vol. 128, no. 1, pp. 132–139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. D. A. Anthoney, M. J. McKean, J. T. Roberts et al., “Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours,” British Journal of Cancer, vol. 90, no. 3, pp. 601–606, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Oliverio, D. Canuti, A. Tononi et al., “Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients,” Journal of Chemotherapy, vol. 11, no. 4, pp. 301–305, 1999. View at Google Scholar · View at Scopus
  54. J. P. Guastalla, E. Pujade-Lauraine, B. Weber et al., “Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study,” Annals of Oncology, vol. 9, pp. 37–43, 1998. View at Google Scholar
  55. L. M. Schuchter, “Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol®),” European Journal of Cancer Part A, vol. 32, supplement 4, pp. S40–S42, 1996. View at Publisher · View at Google Scholar · View at Scopus
  56. W. Grisold, G. Cavaletti, and A. J. Windebank, “Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention,” Journal of Neuro-Oncology, vol. 4, pp. 45–54, 2012. View at Google Scholar
  57. S. Ushio, N. Egashira, H. Sada et al., “Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents,” European Journal of Cancer, vol. 48, pp. 1407–1413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Nishioka, M. Shimada, N. Kurita et al., “The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen,” International Journal of Clinical Oncology, vol. 16, no. 4, pp. 322–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. X. Hu, J. Sato, G. Bajotto et al., “Goshajinkigan (Chinese herbal medicine niu-che-sen-qi-wan) improves insulin resistance in diabetic rats via the nitric oxide pathway,” Nagoya Journal of Medical Science, vol. 72, no. 1-2, pp. 35–42, 2010. View at Google Scholar · View at Scopus
  60. T. Kono, N. Mamiya, N. Chisato et al., “Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer,” Evidence-based Complementary and Alternative Medicine, vol. 2011, Article ID 418481, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Qin, M. Nagasaki, M. Ren et al., “Gosha-jinki-gan (a Herbal Complex) corrects abnormal insulin signaling,” Evidence-Based Complementary and Alternative Medicine, vol. 1, pp. 269–276, 2004. View at Google Scholar
  62. Y. Nagaki, S. Hayasaka, Y. Hayasaka et al., “Effects of Goshajinkigan on corneal sensitivity, superficial punctate keratopathy and tear secretion in patients with insulin-dependent diabetes mellitus,” American Journal of Chinese Medicine, vol. 31, no. 1, pp. 103–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. X. Hu, J. Sato, Y. Oshida, M. Xu, G. Bajotto, and Y. Sato, “Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats,” Diabetes Research and Clinical Practice, vol. 59, no. 2, pp. 103–111, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Suzuki, K. Goto, A. Ishige, Y. Komatsu, and J. Kamei, “Antinociceptive effect of Gosha-jinki-gan, a Kampo medicine, in streptozotocin-induced diabetic mice,” Japanese Journal of Pharmacology, vol. 79, no. 2, pp. 169–175, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Nishizawa, W. H. F. Sutherland, and H. Nukada, “Gosha-jinki-gan (herbal medicine) in streptozocin-induced diabetic neuropathy,” Journal of the Neurological Sciences, vol. 132, no. 2, pp. 177–181, 1995. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Tawata, A. Kurihara, K. Nitta, E. Iwase, N. Gan, and T. Onaya, “The effects of Goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy,” Diabetes Research and Clinical Practice, vol. 26, no. 2, pp. 121–128, 1994. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Takashima, “Application of Goshajinkigan to the peripheral neuropathy of paclitaxel in a breast cancer,” Clinical Cancer Research, vol. 51, pp. 58–59, 2005. View at Google Scholar
  68. T. Yamamoto, T. Murai, M. Ueda et al., “Clinical features of paclitaxel-induced peripheral neuropathy and role of Gosya-jinki-gan,” Gan To Kagaku Ryoho, vol. 36, no. 1, pp. 89–92, 2009. View at Google Scholar · View at Scopus
  69. M. Nishioka, M. Shimada, N. Kurita et al., “The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen,” International Journal of Clinical Oncology, vol. 16, no. 4, pp. 322–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Kono, N. Mamiya, N. Chisato et al., “Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 418481, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Oyama, T. Isono, Y. Suzuki, and Y. Hayakawa, “Anti-nociceptive effects of aconiti tuber and its alkaloids,” American Journal of Chinese Medicine, vol. 22, no. 2, pp. 175–182, 1994. View at Google Scholar · View at Scopus
  72. K. Yamamoto, H. Hoshiai, and K. Noda, “Effects of Shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin,” Gynecologic Oncology, vol. 81, no. 2, pp. 333–334, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Yamamoto, T. Abe, K. Fujii et al., “Examination about a cancer chemotherapy enforcement case including the usefulness Paclitaxel of the Chinese medicine to numbness and muscular pain,” Obstetrics and Gynecology in Chinese Medicine, vol. 17, pp. 24–27, 2000. View at Google Scholar
  74. M. E. Wall, M. C. Wani, C. E. Cook, K. H. Palmer, A. T. McPhail, and G. A. Sim, “Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata,” Journal of the American Chemical Society, vol. 88, no. 16, pp. 3888–3890, 1966. View at Google Scholar · View at Scopus
  75. G. G. Chabot, “Clinical pharmacokinetics of irinotecan,” Clinical Pharmacokinetics, vol. 33, no. 4, pp. 245–259, 1997. View at Google Scholar · View at Scopus
  76. S. Gail Eckhardt, “Irinotecan: a review of the initial phase I trials,” Oncology, vol. 12, no. 8, pp. 31–38, 1998. View at Google Scholar · View at Scopus
  77. J. G. Kuhn, “Pharmacology of irinotecan,” Oncology, vol. 12, pp. 39–42, 1998. View at Google Scholar
  78. J. Randolph Hecht, “Gastrointestinal toxicity of Irinotecan,” Oncology, vol. 12, no. 8, pp. 72–78, 1998. View at Google Scholar · View at Scopus
  79. S. Wadler, A. B. Benson III, C. Engelking et al., “Recommended guidelines for the treatment of chemotherapy-induced diarrhea,” Journal of Clinical Oncology, vol. 16, no. 9, pp. 3169–3178, 1998. View at Google Scholar · View at Scopus
  80. Y. Sugiyama, Y. Kato, and X.-Y. Chu, “Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein,” Cancer Chemotherapy and Pharmacology, vol. 42, no. 1, supplement, pp. S44–S49, 1998. View at Google Scholar · View at Scopus
  81. R. J. Cersosimo, “Irinotecan: a new antineoplastic agent for the management of colorectal cancer,” Annals of Pharmacotherapy, vol. 32, no. 12, pp. 1324–1333, 1998. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Ogawa, “Novel anticancer drugs in Japan,” Journal of Cancer Research and Clinical Oncology, vol. 125, no. 3-4, pp. 134–140, 1999. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Bleiberg, “CPT-11 in gastrointestinal cancer,” European Journal of Cancer, vol. 35, no. 3, pp. 371–379, 1999. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Fukuoka, N. Masuda, S. Kudoh, and S. Negoro, “Irinotecan in small-cell lung cancer—Japanese trials,” Oncology, vol. 14, no. 7, pp. 57–62, 2000. View at Google Scholar · View at Scopus
  85. Y. Ando, H. Saka, M. Ando et al., “Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis,” Cancer Research, vol. 60, no. 24, pp. 6921–6926, 2000. View at Google Scholar · View at Scopus
  86. J. R. Murren, K. Blum, M. Gallipoli, A. Mckeon, and R. Rich, “Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule,” Oncology, vol. 15, no. 1, pp. 25–30, 2001. View at Google Scholar · View at Scopus
  87. A. Font, J. M. Sanchez, R. Rosell et al., “Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors,” Lung Cancer, vol. 37, no. 2, pp. 213–218, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Fujii, M. Koshiyama, M. Konishi, M. Yoshida, and K. Tauchi, “Intermittent, repetitive administrations of irinotecan (CPT- 11) reduces its side-effects,” Cancer Detection and Prevention, vol. 26, no. 3, pp. 210–212, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. G. Toffoli, E. Cecchin, G. Corona, and M. Boiocchi, “Pharmacogenetics of irinotecan,” Current Medicinal Chemistry, vol. 3, no. 3, pp. 225–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. A. B. Benson III, J. A. Ajani, R. B. Catalano et al., “Recommended guidelines for the treatment of cancer treatment-induced diarrhea,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2918–2926, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. R. Sharma, P. Tobin, and S. J. Clarke, “Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea,” The Lancet Oncology, vol. 6, no. 2, pp. 93–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. K. K. Hahn, J. J. Wolff, and J. M. Kolesar, “Pharmacogenetics and irinotecan therapy,” American Journal of Health-System Pharmacy, vol. 63, no. 22, pp. 2211–2217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Richardson and R. Dobish, “Chemotherapy induced diarrhea,” Journal of Oncology Pharmacy Practice, vol. 13, no. 4, pp. 181–198, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Hind, P. Tappenden, I. Tumur, S. Eggington, P. Sutcliffe, and A. Ryan, “The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation,” Health Technology Assessment, vol. 12, no. 15, pp. 1–182, 2008. View at Google Scholar · View at Scopus
  95. P. Biason, S. Masier, and G. Toffoli, “UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity,” Journal of Chemotherapy, vol. 20, no. 2, pp. 158–165, 2008. View at Google Scholar · View at Scopus
  96. G. E. Palomaki, L. A. Bradley, M. P. Douglas, K. Kolor, and W. D. Dotson, “Can UCT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review,” Genetics in Medicine, vol. 11, no. 1, pp. 21–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. Z.-Y. Hu, Q. Yu, and Y.-S. Zhao, “Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis,” European Journal of Cancer, vol. 46, no. 10, pp. 1856–1865, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. K.-I. Fujita and A. Sparreboom, “Pharmacogenetics of irinotecan disposition and toxicity: a review,” Current Clinical Pharmacology, vol. 5, no. 3, pp. 209–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. M. M. Dias, R. A. McKinnon, and M. J. Sorich, “Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis,” Pharmacogenomics, vol. 13, pp. 889–899, 2012. View at Google Scholar
  100. Y. Kito and N. Teramoto, “Effects of Hange-shashin-to (TJ-14) and Keishi-ka-shakuyaku-to (TJ-60) on contractile activity of circular smooth muscle of the rat distal colon,” American Journal of Physiology, vol. 303, pp. 1059–1066, 2012. View at Google Scholar
  101. Y. Kase, T. Hayakawa, M. Aburada, Y. Komatsu, and T. Kamataki, “Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat,” Japanese Journal of Pharmacology, vol. 75, no. 4, pp. 407–413, 1997. View at Google Scholar · View at Scopus
  102. Y. Kase, T. Hayakawa, A. Ishige, M. Aburada, and Y. Komatsu, “The effects of Hange-shashin-to on the content of prostaglandin E2 and water absorption in the large intestine of rats,” Biological & Pharmaceutical Bulletin, vol. 20, no. 9, pp. 954–957, 1997. View at Google Scholar · View at Scopus
  103. Y. Kase, T. Hayakawa, S. Takeda, A. Ishige, M. Aburada, and M. Okada, “Pharmacological studies on antidiarrheal effects of Hange-shashin-to,” Biological & Pharmaceutical Bulletin, vol. 19, no. 10, pp. 1367–1370, 1996. View at Google Scholar · View at Scopus
  104. K. Takasuna, Y. Kasai, Y. Kitano et al., “Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats,” Japanese Journal of Cancer Research, vol. 86, no. 10, pp. 978–984, 1995. View at Google Scholar · View at Scopus